Application of Epstein-Barr Virus Serology to the Diagnosis and Staging of North American Patients with Nasopharyngeal Carcinoma

1983 ◽  
Vol 91 (3) ◽  
pp. 255-262 ◽  
Author(s):  
H. Bryan Neel ◽  
Gary R. Pearson ◽  
Louis H. Weiland ◽  
William F. Taylor ◽  
Helmut H. Goepfert ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
North American ◽  
Epstein Barr Virus ◽  
Geometric Mean ◽  
World Health ◽  
Barr Virus ◽  
Staging Systems ◽  
Antibody Titers ◽  
Epstein Barr

From 1978 to 1981, 151 patients with nasopharyngeal carcinoma (NPC) were enrolled in a prospective, collaborative study of North American patients, most of them white. Thirty-seven had World Health Organization (WHO) type 1 tumors, and 114 had WHO types 2 and 3 tumors. The anti-Epstein-Barr virus (EBV) profile of elevated antibody titers directed against viral capsid antigen and early antigen was seen in 85% of the patients with WHO types 2 and 3 tumors but in only 16% of the patients with WHO type 1 tumors. Geometric mean titers tended to be higher in higher stages of the disease in several staging systems. Low antibody-dependent cellular cytotoxicity at diagnosis appears to reflect a poorer prognosis, and the determination of antibody titers by this assay may prove to be useful for identifying persons in whom recurrent disease is likely to develop after conventional therapy. Anti-EBV titers can aid in diagnosis and treatment planning in patients with NPC, particularly those with occult primary NPC.

PO-098: Epstein-Barr Virus Latent Membrane Protein Type 1 (LMP1) Expression in Non Endemic Nasopharyngeal Carcinoma

2013 ◽  
Vol 106 ◽  
pp. S41-S42
Author(s):  
S. Rosales-Pérez ◽  
A. Calva-Espinoza ◽  
A. Daidone ◽  
C.H. Flores-Balcázar ◽  
F. Guedea-Edo ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Membrane Protein ◽  
Epstein Barr Virus ◽  
Latent Membrane Protein ◽  
Barr Virus ◽  
Lmp1 Expression ◽  
Epstein Barr ◽  
Virus Latent Membrane Protein ◽  
Membrane Protein Type

Immunologic Detection of Occult Primary Cancer of the Head and Neck

1981 ◽  
Vol 89 (2) ◽  
pp. 230-234 ◽  
Author(s):  
H. Bryan Neel ◽  
Gary R. Pearson ◽  
Louis H. Weiland ◽  
William F. Taylor ◽  
Helmuth H. Goepfert
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Head And Neck ◽  
Epstein Barr Virus ◽  
Testing Procedure ◽  
Primary Cancer ◽  
Diagnostic Aid ◽  
Barr Virus ◽  
Antibody Titers ◽  
Epstein Barr ◽  
Obvious Source

Because antibody titers against Epstein-Barr virus (EBV) antigens often are elevated in patients with active undifferentiated and nonkeratinizing nasopharyngeal carcinoma, anti-EBV serologic tests have been applied as a diagnostic aid in patients who have metastatic lymphadenopathy in the neck without an obvious source. In this study of 44 patients, the serologic testing procedure proved useful in identifying six patients with nasopharyngeal carcinoma that was initially occult but was eventually confirmed by biopsy.

Nasopharyngeal carcinoma in american children: Epstein-Barr virus-specific antibody titers and prognosis

1982 ◽  
Vol 29 (2) ◽  
pp. 209-212 ◽  
Author(s):  
Robert F. Naegele ◽  
John Champion ◽  
Sharon Murphy ◽  
Gertrude Henle ◽  
Werner Henle
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Specific Antibody ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Virus Specific Antibody ◽  
Antibody Titers ◽  
Epstein Barr ◽  
American Children

scholarly journals Epstein-Barr virus and familial Hodgkin's disease

Blood ◽  
1996 ◽  
Vol 88 (8) ◽  
pp. 3160-3165 ◽  
Author(s):  
AY Lin ◽  
DW Kingma ◽  
ET Lennette ◽  
TR Fears ◽  
JM Whitehouse ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Epstein Barr Virus ◽  
Hodgkin’S Disease ◽  
Geometric Mean ◽  
Barr Virus ◽  
Tumor Tissues ◽  
Antibody Titers ◽  
Lower Titer ◽  
Epstein Barr ◽  
And Control

Several studies suggest that the Epstein-Barr virus (EBV) is etiologically linked to Hodgkin's disease (HD). This study was undertaken to examine the role of EBV in familial HD (FHD). Among 60 FHD patients from 27 families with two or more cases per family, we tested available paraffinized tumor tissues from 46 cases by in situ hybridization for EBV-encoded RNA (EBER1) expression. Thirteen of 46 FHD patients (28%) had EBER1 expressed in the Reed-Sternberg cells. Concordance rate of EBV positivity was evaluated among 34 first-degree related pairs from 17 families for which both cases had available paraffinized tumor tissues. Only two of 17 pairs were concordant for EBER1 positivity. There was no excess of positive concordance (P = .18). Serologically, FHD patients had higher geometric mean antibody titers (GMTs) to the viral capsid antigen (VCA) and early antigen D (EA-D). There was no difference in seroprevalence between patients and control groups, nor was there concordance in elevated serology among 15 pairs of first-degree related FHD cases. Young adult unaffected family members (UFM) may not react to EBV in the same way as the general population as evidenced by the lower titer of VCA, although not statistically significant, and significantly lower titers of EA-D, compared with age-matched controls. While EBV might have some role in a subset of HD, lack of concordance of EBER1 expression and EBV serology among the FHD cases in the same family suggest that EBV does not play an important role in FHD.

Relationship between nasopharyngeal carcinoma and high antibody titers to epstein-barr virus-specific thymidine kinase

1989 ◽  
Vol 43 (1) ◽  
pp. 45-48 ◽  
Author(s):  
Mireille De Turenne-Tessier ◽  
Tadamasa Ooka ◽  
Alain Calender ◽  
Guy De The ◽  
Jacques Daillie
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Thymidine Kinase ◽  
Epstein Barr Virus ◽  
High Antibody ◽  
Barr Virus ◽  
Antibody Titers ◽  
Epstein Barr

scholarly journals Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma

2017 ◽  
Vol 58 (4) ◽  
pp. 509-516 ◽  
Author(s):  
Anussara Prayongrat ◽  
Chakkapong Chakkabat ◽  
Danita Kannarunimit ◽  
Pokrath Hansasuta ◽  
Chawalit Lertbutsayanukul
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Treatment Outcomes ◽  
Epstein Barr Virus ◽  
Locally Advanced ◽  
World Health ◽  
Disease Stage ◽  
Dynamic Changes ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr

Abstract Epstein-Barr virus (EBV) DNA has been recognized as a promising tumor marker for nasopharyngeal carcinoma (NPC). This study aims to demonstrate the prevalence of plasma EBV DNA and its temporal correlation with treatment outcomes in the modern era. A total of 204 patients with Stage I–IVB NPC treated with intensity-modulated radiotherapy (IMRT) were enrolled. Quantitative plasma EBV DNA measurement was performed before treatment (pre-IMRT), on the fifth week of radiation (mid-IMRT), at 3 months after radiation (post-IMRT), then every 6 months until disease relapse. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier method. Plasma EBV DNA was detected in 110 patients (53.9%), with a median pre-IMRT EBV DNA level of 8005 copies/ml. Significant correlation was noted between pre-IMRT EBV DNA level and disease stage, but not between pre-IMRT EBV DNA level and World Health Organization classification. With a median follow-up time of 35.1 months, the 3-year PFS and OS rates were higher in the group with undetectable pre-IMRT EBV DNA level compared with in the group in which it was detectable. When classified according to disease stage and pre-IMRT EBV DNA, patients with early disease and detectable pre-IMRT EBV DNA experienced poorer survival than those with locally advanced disease and undetectable pre-IMRT EBV DNA. According to the dynamic changes in EBV DNA level between pre-IMRT and mid/post IMRT, survival was significantly higher in patients who achieved an undetectable level following treatment. On multivariate analysis, post-IMRT EBV DNA level was the strongest predictor of all treatment outcomes (P < 0.001). Our study demonstrated the clinical significance of the plasma EBV DNA level at specific time points, as well as of the dynamic changes in the EBV DNA level. Disappearance of plasma EBV DNA after treatment was associated with better survival.

Sign in / Sign up

Export Citation Format

Share Document